✦ LIBER ✦

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma

✍ Scribed by Meaghan L. Khan; Craig B. Reeder; Shaji K. Kumar; Marthy Q. Lacy; Donna E. Reece; Angela Dispenzieri; Morie A. Gertz; Phillip Greipp; Suzanne Hayman; Steven Zeldenhurst; David Dingli; John Lust; Stephen Russell; Kristina M. Laumann; Joseph R. Mikhael; P. Leif Bergsagel; Rafael Fonseca; S. Vincent Rajkumar; A. Keith Stewart

Book ID: 108677506
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 215 KB
Volume: 156
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2011.08949.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clarithromycin (Biaxin)-lenalidomide-low

Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma

✍ Francesca Gay; S. Vincent Rajkumar; Morton Coleman; Shaji Kumar; Tomer Mark; Ang 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB

Lenalidomide, cyclophosphamide and dexam

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

✍ Shaji K. Kumar; Martha Q. Lacy; Suzanne R. Hayman; Keith Stewart; Francis K. Bua 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

Bortezomib, dexamethasone, cyclophospham

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

✍ Kumar, S K; Flinn, I; Noga, S J; Hari, P; Rifkin, R; Callander, N; Bhandari, M; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 302 KB

Cyclophosphamide, bortezomib and dexamet

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

✍ Reeder, C B; Reece, D E; Kukreti, V; Chen, C; Trudel, S; Hentz, J; Noble, B; Pir 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 141 KB

The addition of cyclophosphamide to lena

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study

✍ Stephen A. Schey; Gareth J. Morgan; Karthik Ramasamy; Beth Hazel; Dariusz Ladon; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB

Bortezomib in combination with dexametha

Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience

✍ Weiyan Zheng; Guoqing Wei; Xiujin Ye; Jingsong He; Li Li; Wenjun Wu; Jimin Shi; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 245 KB

## Objective: Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (mm) with an overall response rate of 92% and a cr rate of 18% (alexanian et al, hematology 2007;12(3):235-9), but this regimen has not been tested in the chinese patients. we re